Trial Profile
A retrospective cohort study evaluating treatment persistence among patients with rheumatic disease treated with subcutaneous TNF inhibitors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary)
- Indications Ankylosing spondylitis; Arthritis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- 02 Nov 2018 New trial record